🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Proud and grateful for the #nejm acknowledgment of my contribution to the Journal's world-class peer review process lnkd.in/gKpiWfeR

It was an honor to present our booster study and discuss the tremendous efforts of Clalit Health Services to fight the #omicron surge in Israel in the joint event of the World Health Organization and #ecdc. Thank you Mark Katz for the opportunity to share…lnkd.in/gjQ6T-3X

x.com/NEJM/status/14…

In the latest Clinical Conversations podcast, Joe Elia and Ali S. Raja, MD sit down with Dr. Ronen Arbel to discuss his study examining #COVID19 #vaccination after infection in Israel. Listen in: jwat.ch/3sS3dVH

During the clinical rollout of nirmatrelvir in Israel in early 2022, most patients (78%) had previous SARS-CoV-2 immunity. Benefit was seen among patients at highest risk for Covid-19 progression, such as those 65+. nej.md/3QUUgWe

Pfizer’s Paxlovid reduces #COVID19 death by 81% in older adults, but has little effect of people under the age of 64. New study by Clalit Research, published in NEJM, written for Health Policy Watch - Global Health News Reporting. healthpolicy-watch.news/nejm-study-pax…

Great honor to be part of this effort, that seems to have contained the #monkeypox epidemic lnkd.in/dHRVrJkM

It was my great pleasure and honor to present the impact of Clalit Health Services research on global policy at the Harvard T.H. Chan School of Public Health Center for Health Decisions Science. lnkd.in/drV9q8AT

Proud to publish our latest manuscript on the latest medications for #weightloss with my colleagues Dr. Ariel Hammerman Dr. Joseph Azuri, Enis Abo Alhasan and Dr. Benni Sluckis, in the esteemed DOM journal lnkd.in/dBBE5qX5

Will be presenting in the #lancet late-breaking at the #eccmid2023 on Monday, April 17 at 4:30 PM lnkd.in/dZQ7-Txw

Today, FDA amended the EUAs of the Pfizer-BioNTech and Moderna COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals. fda.gov/news-events/pr… What you need to know. 🧵👇

It was my great honor today to present the impact of Clalit Health Services research on Global #covidvaccine policy in the presidential session of the German Society of Internal Medicine (DGIM) lnkd.in/dyEeBqqT

Great example of the magic created when you combine clinical insights and data science lnkd.in/d84sy8HG

Proud to share our analysis in the #nejm regarding the need for prioritization of #covidvaccine. The NNT to prevent one #Covid19 death in subjects younger than 65 is over 100,000, costing $12M, prompting the need for prioritizati…lnkd.in/dSMMTsYR lnkd.in/d7J2gMpF

Proud to be part of this important project . lnkd.in/dYGBMtrk

Proud to be part of the editor's choice in the Obesity journal, comparing the #effectiveness and #economics of #weightloss medications. With Prof. Yossi Azuri, Dr. Ariel Hammerman, PhD, Enis Abo Alhasan, and Dr. Benny Slukis. lnkd.in/dS2cYAAf

Proud to achieve the 1,000 citations milestone on Google Scholar lnkd.in/d_XHT65x lnkd.in/dVQn5a_P

It was my great honor to present our #mpox risk assessment study, which affected the national vaccination study at real time, at the annual public health conference. It was a joint effort at Clalit Health Services, translating the amazing insights of…lnkd.in/dZUZpAt5

Amazing comprehensive work by דן ימין Dan Yamin Ronen Arbel + colleagues on booster safety (1st, 2nd, bivalent). Temporary DECREASE in NON-Covid hospitalizations supports idea that infections exacerbate existing medical probs and boosters briefly prevent this. thelancet.com/journals/lanin…

Proud to be part of this research, and to collaborate with this brilliant team lnkd.in/dPV2NHPH